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ABSTRACT
ObjeCtive
To evaluate the association between pioglitazone use 
and bladder cancer risk in patients with type 2 
diabetes.
Design
Retrospective cohort study using propensity score 
matched cohorts.
settings
Healthcare databases from Finland, the Netherlands, 
Sweden, and the United Kingdom. Data comprised 
country specific datasets of linked records on 
prescriptions, hospitals, general practitioners, cancer, 
and deaths.
PartiCiPants
Patients with type 2 diabetes who initiated 
pioglitazone (n=56 337) matched with patients with 
type 2 diabetes in the same country exposed to 
diabetes drug treatments other than pioglitazone 
(n=317 109). Two matched cohorts were created, using 
a 1:1 fixed ratio (nearest match cohort) and a 1:10 
variable ratio (multiple match cohort). Patients were 
matched on treatment history and propensity scores 
accounting for several variables associated with 
pioglitazone initiation.
Main OutCOMe Measures
Hazard ratios and 95% confidence intervals were 
estimated by Cox’s proportional hazards model with 
adjustments for relevant confounders. To assess the 
robustness of the findings, several sensitivity and 
stratified analyses were performed.
results
In the cohort exposed to pioglitazone treatment, 130 
bladder cancers occurred over a mean follow-up time 
of 2.9 years. In the nearest match and multiple match 
cohorts not exposed to pioglitazone treatment, 153 
and 970 bladder cancers were recorded, with a mean 
follow-up time of 2.8 and 2.9 years, respectively. With 
regards to bladder cancer risk, the adjusted hazard 
ratio for patients ever exposed versus never exposed 
to pioglitazone was 0.99 (95% confidence interval 
0.75 to 1.30) and 1.00 (0.83 to 1.21) in the nearest and 
multiple match cohorts, respectively. Increasing 
duration of pioglitazone use and increasing cumulative 
dose were not associated with risk of bladder cancer 
(>48 months of pioglitazone use, adjusted hazard ratio 
0.86 (0.44 to 1.66); >40 000 mg cumulative dose, 0.65 
(0.33 to 1.26) in the nearest match cohort).
COnClusiOns
This study shows no evidence of an association 
between ever use of pioglitzone and risk of bladder 
cancer compared with never use, which is consistent 
with results from other recent studies that also 
included a long follow-up period.
trial registratiOn
Registered to the European Union electronic register of 
post-authorisation studies (EU PAS register no 
EUPAS3626).
Introduction
Pioglitazone is a drug from the thiazolidinediones class 
that is used for the treatment of type 2 diabetes melli‑
tus. Whether pioglitazone use causes an increased risk 
of developing bladder cancer has been debated for sev‑
eral years. In the two year, prospective, macrovascular 
events outcome clinical trial (PROactive), researchers 
observed an excess of bladder cancers among patients 
treated with pioglitazone versus placebo (14 v six).1 
However, 11 cancers in the pioglitazone group occurred 
during the first year of treatment, including two diag‑
nosed 13 and 14 days into the trial, another at one 
month, a fourth at three months, and a fifth at four 
months. Increased risk of urothelial cancers requires 
long exposure to risk factors, thus it is considered not 
plausible that these early cancers could be due to 
pioglitazone.2 Long term follow‑up of the PROactive 
trial participants found no imbalance in bladder can‑
cers between the pioglitazone versus placebo groups 
(23 v 22).3
Multiple epidemiological studies, and meta‑analyses 
of these studies, have investigated pioglitazone use and 
WhAT IS AlReAdy knoWn on ThIS TopIC
Many earlier epidemiological studies have reported an increased bladder cancer 
risk in patients with type 2 diabetes using pioglitazone
However, several of these early studies had little control of treatment allocation 
bias or had no information on known risk factors of bladder cancer
Recent large studies with longer follow-up have reported no association between 
pioglitazone exposure and bladder cancer risk
WhAT ThIS STudy AddS
This analysis of datasets from Finland, Sweden, the Netherlands, and the UK shows 
no evidence of an association between ever use of pioglitazone and risk of bladder 
cancer, compared with never use
Results indicate that longer duration of pioglitazone use does not increase the risk 
of bladder cancer
These results provide additional important information on the safety of 
pioglitazone use in Europe
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bladder cancer.4‑6  Most studies had short term exposure 
and follow‑up but observed a positive association, and 
the meta‑analyses show a pooled risk estimate of 1.2. 
Based on these early studies, some commentators have 
opined that it can confidently be assumed that pioglita‑
zone increases the risk of bladder cancer.7  A recent 
evaluation by the International Agency for Research on 
Cancer observed a positive association between piogli‑
tazone and bladder cancer, but was unable to consis‑
tently rule out confounding, selection bias, detection 
bias, and bias related to indication or severity of disease 
in the populations studied as potential explanations for 
positive associations with the drug.8
More recently, second generation epidemiology stud‑
ies have been undertaken, built on the knowledge and 
understanding of limitations of earlier studies. A large, 
long term prospective cohort study using the Kaiser Per‑
manente Northern California (KPNC) database of health 
insurance claims was conducted at the request of the 
US Food and Drug Administration and European Medi‑
cines Agency. Increased risk of bladder cancer was 
observed in the KPNC study with at least two years of 
pioglitazone use at a five year interim analysis,9  how‑
ever, no increase was apparent in the 10 year analysis 
for ever exposure to pioglitazone or for duration or 
cumulative dose of pioglitazone.10  Two large, long term 
cohort studies have also recently reported no associa‑
tion between bladder cancer and pioglitazone,11 12  while 
one recent study has reported a positive association.13
Pharmacoepidemiology studies of drug effects are 
particularly prone to treatment allocation bias, which 
can result in detection of false associations. In Europe, 
pioglitazone is predominantly a second or third line 
treatment used particularly for overweight patients 
with diabetes who have failed to achieve or maintain 
good glycaemic control with metformin or a sulphony‑
lurea. Thus, patients initiating pioglitazone treatment 
could have a longer diabetes duration, longer duration 
of poor glycaemic control, and more diabetic complica‑
tions than other patients. These underlying characteris‑
tics could independently be associated with an increase 
in bladder cancer risk. Designs or statistical methods 
minimalising the effects of treatment allocation bias 
were not incorporated in several of the previous studies.
Most recent studies have observed no association 
between pioglitazone use and increased risk of bladder 
cancer, whereas several earlier studies have reported a 
positive association. To better understand whether the 
earlier reported association was real or due to confound‑
ing and bias, the European Medicines Agency requested 
a study. Our study was undertaken by a consortium of 
European pharmacoepidemiologists using healthcare 
data from Finland, the Netherlands, Sweden, and the 
UK. We present a propensity score matched cohort 
design in which patients initiating pioglitazone treat‑
ment have been matched to patients with a similar clin‑
ical history initiating alternative diabetic medications.
Methods
This study had a retrospective matched cohort design 
and was undertaken in six non‑overlapping popula‑
tions from four European countries: Finland, the Neth‑
erlands, Sweden, and the UK. We used the PHARMO 
database network for the Netherlands datasets, the 
Clinical Practice Research Datalink GOLD database for 
the UK general practitioner (GP) dataset, and Clinical 
Practice Research Datalink GOLD‑Hospital Episode Sta‑
tistics was used for the UK GP‑hospital dataset. Table 1 
presents used data sources and study periods, and the 
supplementary appendix provides further details. Drug 
use data were based on outpatient prescription data in 
the Netherlands GP, UK GP‑hospital, and UK GP data‑
sets, and based on outpatient dispensing data in the 
other datasets. Morbidity data were based solely on GP 
records in the Netherlands GP and UK GP datasets and 
on hospital records in the Finland, Sweden, and 
 Netherlands hospital datasets, but based on both GP 
and hospital data in the UK GP‑hospital dataset. Blad‑
der cancer cases were identified from cancer registries 
in the Finland, Sweden, and UK GP‑hospital datasets, 
from hospital records in the Netherlands hospital data‑
set, and from GP records in the Netherlands GP and 
UK  GP datasets. For cancer registers, reporting is 
 compulsory, with coverage close to 100%.14‑16  In the UK 
table 1 | Data sources used in each population. start and end of follow-up together with dates on availability of morbidity and prescription data at baseline
Country, dataset Data sources
start of treatment and 
morbidity records
earliest possible 
cohort entry date end of follow-up
Finland Linked national databases: Finnish prescription register, Finnish registry for 
reimbursed drug treatments, Finnish cancer registry, Finnish hospital care register 
(inpatient and outpatient), Finnish institutional care register, Finnish causes of 
death register
1 January 1998 1 January 2002 30 June 2011
Sweden Linked national databases: Swedish prescribed drug register, Swedish cancer 
register, Swedish national patient register (inpatient and outpatient hospital 
visits), Swedish cause of death register, Swedish national diabetes register, 
Swedish total population register
1 July 2005 1 July 2006 30 June 2011
Netherlands, 
hospital
PHARMO outpatient pharmacy database linked to national medical registry from 
the Dutch Hospital Data Foundation (hospital admissions) and Central Bureau of 
Genealogy registry (mortality)
1 January 1995 1 January 2002 30 June 2011
Netherlands, GP PHARMO GP database 1 January 2002 1 January 2003 30 June 2011
UK, GP-hospital Portion of CPRD GOLD database with linkage to Hospital Episode Statistic data, 
cancer registry data, and death certificate data
1 January 1987 1 January 2000 31 December 2010
UK, GP Remainder of CPRD GOLD database 1 January 1987 1 January 2000 30 June 2011
CPRD=Clinical Practice Research Datalink.
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GP dataset, a recent validation study reported over 91% 
coverage compared with the cancer registry data.17
We identified all patients with type 2 diabetes melli‑
tus over age 40 years who initiated or switched to piogl‑
itazone treatment (that is, pioglitazone exposed 
patients) or to any other diabetic treatment excluding 
pioglitazone (that is, non‑exposed patients) during the 
study period. Patients’ cohort entry dates among the 
exposed patients was the date of first pioglitazone pre‑
scription. Patients not exposed to pioglitazone could 
have initiated drugs at multiple time points during the 
study period, all of which were treated as possible 
cohort entry dates. To ensure that the patients were new 
initiators, a minimum 12 month membership in the 
treatment database with no pioglitazone exposure was 
required before the possible cohort entry date. We 
excluded all potential cohort entry dates associated 
with a shorter than 12 month membership in the treat‑
ment database. In addition, we excluded entry dates 
associated with any of the following histories: 
•	 Diagnosis of malignant or benign bladder neoplasms
•	 Secondary malignancies of the bladder
•	 Neoplasms of uncertain or unknown behaviour of the 
bladder
•	 Partial or complete resection of the bladder
•	 Biopsy of bladder tumour or lesion. 
We also excluded cohort entry dates that occurred 
during the use of any other drug from the thiazolidine‑
dione group.
Each pioglitazone exposed patient was matched with 
the closest corresponding non‑exposed patients (that 
is, who were not exposed to pioglitazone) to a 1:1 fixed 
ratio (nearest match cohort) and 1:10 variable ratio 
(multiple match cohort).18 For many pioglitazone 
exposed patients, fewer than 10 matches were identi‑
fied and included. Patients were matched on the basis 
of propensity scores and on the following exact match‑
ing variables: antidiabetic treatment immediately 
before the cohort entry date, whether the treatment 
change at the cohort entry date was an add‑on or 
switch‑in treatment, and use of thiazolidinediones 
before the cohort entry date. The propensity score was 
based on the exact matching variables and the follow‑
ing baseline variables: 
•	 Duration of treated diabetes 
•	 Duration of prescription database membership
•	 Number of different diabetes treatments used before 
the cohort entry date
•	 Calendar year of the cohort entry date
•	 History of myocardial infarction 
•	 Stroke 
•	 Heart failure
•	 Diabetic complications, as follows: retinopathy or 
maculopathy, severe lower limb complications, renal 
complications, ketoacidosis, and hyperosmolar or 
ketoacidotic coma. 
In all countries, the propensity score and matching 
were based on the same variables. Because the num‑
ber of available matched patients not exposed to 
 pioglitazone varied between countries, the primary 
analysis was based on the nearest match cohort.
Each patient was followed from cohort entry date to 
the date of diagnosis of the first incident bladder can‑
cer, end of database membership, death, start of treat‑
ment with another thiazolidinedione, or end of study 
period. Use of diabetic drugs were treated as time 
updating variables. We determined drug exposure peri‑
ods on the basis of the dispended amount and dose. 
Pioglitazone exposure was measured by three different 
variables: never versus ever exposed, cumulative dura‑
tion of exposure, and cumulative dose. Other relevant 
comorbidities and other drug treatments (supplemen‑
tary table 3) were each treated as time dependent binary 
(ever v never) variables. The country specific cohorts 
were ultimately pooled and analysed as a single data‑
set. In a sensitivity analysis, cumulative duration of 
insulin exposure, glycated haemoglobin (HbA1C), 
smoking, and body mass index were included as cate‑
gorical variables.
statistical methods
Propensity scores (the probabilities to initiate pioglita‑
zone treatment at the cohort entry date) were estimated 
using logistic regression. The covariates included in the 
model are listed above and in supplementary table 2. 
We fitted the propensity score model by using baseline 
characteristics at the cohort entry date for the pioglita‑
zone exposed patients and those at the potential cohort 
entry dates of the non‑exposed patients.
Matching was based on both exact matching vari‑
ables and distance within a caliper in the propensity 
score. The first round of matching was used as the 1:1 
fixed ratio matched cohort, and the full matching 
resulted in the 1:10 variable ratio matched cohort. 
Details on the matching variables and algorithm are 
provided in the supplementary material.
We used descriptive statistics to characterise the 
study cohorts. Differences were quantified using stan‑
dardize differences, with a score under 10 indicating 
good balance. Crude bladder cancer incidence rates 
with 95% confidence intervals were calculated.
To generate hazard ratios, we used Cox’s propor‑
tional hazards model, adjusted for baseline and time 
dependent covariates. The base model included the 
ever versus never exposed to pioglitazone variable and 
a dataset population categorical variable. The adjusted 
model included age, sex, diabetic drug treatments, 
exact matching variables, groups based on quintiles of 
propensity scores, all variables used in the propensity 
score, plus possible confounding variables.18 19 The pro‑
pensity score variables that are indicators of comorbid‑
ities enter the model as time dependent variables 
(supplementary table 2). Confounders were defined as 
those variables that caused a minimum 10% shift in the 
hazard ratio for pioglitazone exposure.
For the multiple match cohort, the imbalance due to 
varying matching ratio was accounted for by the use of 
balancing weights corresponding to the 1:10 variable 
ratio matching in the Cox’s proportional hazards analy‑
sis and in calculations of standardised differences.18
doi: 10.1136/bmj.i3903 | BMJ 2016;354:i3903 | the bmj
RESEARCH
4
We did a meta‑analysis of the population specific 
hazard ratios by using a fixed effect model and a ran‑
dom effects model, with the assumption that each data‑
set has its own effect. Heterogeneity was quantified by 
the I2 statistic.20
Data on smoking, body mass index, and HbA1C were 
not available for the Finland population and the Neth‑
erlands hospital population. Therefore, we did not 
adjust primary analyses for these variables. Sensitivity 
analyses were undertaken in the remaining four popu‑
lations to assess potential confounding. Missing values 
of available variables were treated as a separate cate‑
gory. Several preplanned sensitivity analyses evaluated 
robustness of the results with respect to outcome, expo‑
sure, and follow‑up definitions, and many stratified 
analyses assessed risk modification. We undertook all 
sensitivity analyses using the nearest match cohort. 
Further details on the methodology are provided in the 
supplementary material.
Patient involvement
Our study was a secondary data analysis and did not 
include patients as study participants. No patients were 
involved in setting the research question or the outcome 
measures, nor were they involved in the design and 
implementation of the study. There are no plans to 
involve patients in the dissemination of results, nor will 
we disseminate results directly to the patients.
Results
A total of 1 629 409 treated patients with type 2 diabetes 
constituted the source population. After applying 
exclusion criteria, we identified 61 587 patients exposed 
to pioglitazone, 56 337 of whom we were able to match 
to at least one patient not exposed to pioglitazone 
(table 2). In total, we identified 317 109 non‑pioglitazone 
exposed multiple matches.
Tables 3 and 4 provide descriptive summaries of the 
baseline variables used in the matching. The stan‑
dardised differences were low, indicating that the groups 
exposed and not exposed to pioglitazone were well 
matched regarding baseline characteristics. Duration of 
the treated diabetes (that is, time since the initiation of 
the first diabetes drug) was comparable between the 
exposed groups, with 7805 (14%) and 7883 (14%) patients 
having treated diabetes for less than one year and 18 788 
(33%) and 18 786 (33%) for more than six years in the 
exposed and non‑exposed groups, respectively.
Table 5 shows the distribution of other variables at 
cohort entry. The mean age at the cohort entry date was 
table 2 | Patient selection from source population to matched cohorts in each dataset
Cohort
Dataset
Finland sweden netherlands hospital netherlands gP uK gP uK gP-hospital total
Diabetic patients who initiated or switched treatment
Source population 438 229 295 001 208 962 63 284 317 632 306 301 1 629 409
eligible patients after applying all exclusion criteria
Exposed to pioglitazone 18 794 3712 9081 2829 12 662 14 504 61 587
Not exposed to pioglitazone 332 255 224 742 131 028 42 174 70 471 78 037 878 707
Cohort sizes after matching*
Exposed to pioglitazone 18 794 3 712 7491 (8965) 2823 11 408 12 109 56 337
Not exposed to pioglitazone
 Nearest matched cohort 18 794 3 712 7491 (8965) 2823 11 408 12 109 56 337
 Multiple matched cohort 157 263 31 040 42 048 (50 493) 15 775 35 799 35 184 317 109
*Numbers in parentheses are the cohort size before overlap between Netherland cohorts was removed.
table 3 | Distribution of number of patients for exact matching variables at cohort entry date
Pioglitazone cohort (no (%) of patients) standardised difference
exposed to 
pioglitazone 
(n=56 337)
not exposed to 
pioglitazone 
(nearest match 
cohort; n=56 337)
not exposed to 
pioglitazone 
(multiple match 
cohort; n=317 109)
nearest 
match 
cohort
Multiple 
match 
cohort
type of treatment change at cohort entry date
Add-on 36 237 (64.32) 36 237 (64.32) 212 245 (66.93) 0.00 0.00
Switch 20 100 (35.68) 20 100 (35.68) 104 864 (33.07) 0.00 0.00
use of another thiazolidinedione before cohort entry date
Never 41 847 (74.28) 41 847 (74.28) 276 452 (87.18) 0.00 0.00
Ever 14 490 (25.72) 14 490 (25.72) 40 657 (12.82) 0.00 0.00
Diabetes treatment taken immediately before cohort entry date*
Metformin only 16 526 (29.33) 16 526 (29.33) 115 003 (36.27) 0.00 0.00
Sulphonylureas only 6110 (10.85) 6110 (10.85) 36 673 (11.56) 0.00 0.00
Metformin and sulphonylureas 14 277 (25.34) 14 277 (25.34) 61 494 (19.39) 0.00 0.00
Insulin (only or in combination) 2705 (4.80) 2705 (4.80) 16 940 (5.34) 0.00 0.00
Other drugs (one drug only or combination 10 062 (17.86) 10 062 (17.86) 31 743 (10.01) 0.00 0.00
No treatment 6657 (11.82) 6657 (11.82) 55 256 (17.42) 0.00 0.00
*Treatments initiated at cohort entry date not included.
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63.2 years in the cohort exposed to pioglitazone, and 
65.4 and 66.6 years in the nearest and multiple matches 
of cohorts not exposed to pioglitazone, respectively. The 
pioglitazone exposed cohort also had fewer patients 
aged over 70 years than the non‑exposed cohorts.
The group of patients exposed to pioglitazone had 
130 incident bladder cancers with a crude incidence of 
7.97 per 10 000 person years; the nearest and multiple 
matched cohorts of patients not exposed to pioglita‑
zone had 153 and 970 bladder cancers with crude inci‑
dence of 9.62 and 10.65 per 10 000 person years, 
respectively (table 6). Duration of follow‑up was similar 
between cohorts, with a mean (maximum) of 2.9 (10.5) 
years in the exposed group, and 2.8 (10.8) and 2.9 (11.3) 
years in the nearest and multiple matched cohorts in 
the non‑exposed group, respectively. In the exposed 
group, crude incidence ranged across populations from 
4.4 to 20.7 per 10 000 person years, whereas in the 
non‑exposed group, crude incidence ranged from 5.5 to 
16.0 per 10 000 person years. No difference existed 
between groups in the time to bladder cancer, with 
about 16% occurring within the first six months and 
about 25% within the first 12 months (supplementary 
material).
Figures 1 and 2 present adjusted risk estimates of 
bladder cancer for the pooled data. Ever exposure to 
pioglitazone was not associated with risk of bladder 
cancer (hazard ratio 0.99 (95% confidence interval 0.75 
to 1.30) and 1.00 (0.83 to 1.21) for nearest match and 
multiple match cohorts, respectively). We saw no evi‑
dence of increasing risk with increasing duration of 
pioglitazone treatment (Ptrend=0.42 and 0.85) or with 
cumulative pioglitazone dose (Ptrend=0.45 and 0.81) for 
nearest match and multiple match cohorts, respec‑
tively. Patients with more than 48 months of pioglita‑
zone exposure had adjusted hazard ratios of 0.86 
table 4 | Distribution of propensity score variables for matched cohorts (exposed versus not exposed to pioglitazone) at cohort entry date
Pioglitazone cohort (no (%) of patients)
standardised 
difference
exposed to 
pioglitazone 
(n=56 337)
not exposed to 
pioglitazone 
(nearest match 
cohort; n=56 337)
not exposed to 
pioglitazone 
(multiple match 
cohort; n=317 109)
nearest 
match 
cohort
Multiple 
match 
cohort
Duration of treated diabetes at cohort entry date (years)
<1 7805 (13.85) 7883 (13.99) 67 091 (21.16) 0.40 0.91
1 to <2 6943 (12.32) 6679 (11.86) 37 879 (11.95) 1.44 1.40
2 to <4 11 865 (21.06) 11 578 (20.55) 58 668 (18.50) 1.26 1.69
4 to <6 10 936 (19.41) 11 411 (20.25) 60 944 (19.22) 2.11 1.77
≥6 18 788 (33.35) 18 786 (33.35) 92 527 (29.18) 0.01 0.26
Range 0.00-34.18 0.00-24.79 0.00-24.79 — —
Mean (standard deviation) 4.72 (3.65) 4.78 (3.70) 4.16 (3.54) — —
Median (interquartile range) 4.12 (1.76-6.97) 4.19 (1.82-6.97) 3.59 (1.13-6.27) — —
Diabetes complications at cohort entry date
Diabetic retinopathy or maculopathy 5747 (10.20) 5953 (10.57) 22 040 (6.95) 1.20 1.33
Lower limb severe complications 1308 (2.32) 1530 (2.72) 7521 (2.37) 2.52 2.88
Diabetic renal complications 4771 (8.47) 4870 (8.64) 17 526 (5.53) 0.63 1.51
Ketoacidosis 112 (0.20) 145 (0.26) 916 (0.29) 1.23 1.70
Hyperosmolar or ketoacidotic coma 822 (1.46) 1280 (2.27) 9053 (2.85) 6.01 4.04
Other comorbidities at cohort entry date
Myocardial infarction or stroke 4676 (8.30) 6112 (10.85) 37 213 (11.74) 8.67 9.59
Congestive heart failure 1674 (2.97) 3077 (5.46) 22 181 (6.99) 12.42 14.06
Year at cohort entry date
2000-03 3960 (7.03) 6485 (11.51) 42 671 (13.46) 15.50 15.78
2004-07 21 151 (37.54) 20 513 (36.41) 112 928 (35.61) 2.35 3.36
2008-11 31 226 (55.43) 29 339 (52.08) 161 510 (50.93) 6.72 5.93
Duration of treatment database membership before cohort entry date (years)
1 to 2 5621 (9.98) 5770 (10.24) 30 884 (9.74) 0.88 1.18
3 to 4 6216 (11.03) 6998 (12.42) 38 421 (12.12) 4.32 4.15
5 to 6 7802 (13.85) 9962 (17.68) 58 311 (18.39) 10.54 9.18
≥7 36 698 (65.14) 33 607 (59.65) 189 493 (59.76) 11.35 10.37
Range 1.00-22.00 1.00-23.00 1.00-23.00 — —
Mean (standard deviation) 8.39 (4.35) 8.14 (4.36) 8.06 (4.06) — —
Median (interquartile range) 8.00 (5.00-11.00) 8.00 (5.00-11.00) 8.00 (5.00-12.00) — —
no of different diabetes drug classes ever used before cohort entry date
0 2260 (4.01) 2253 (4.00) 25 397 (8.01) 0.06 2.51
1 14 970 (26.57) 14 129 (25.08) 113 404 (35.76) 3.41 1.33
2 25 185 (44.70) 24 068 (42.72) 114 283 (36.04) 4.00 5.77
3 11 052 (19.62) 12 046 (21.38) 50 098 (15.80) 4.37 3.60
>3 2870 (5.09) 3841 (6.82) 13 927 (4.39) 7.29 6.34
Data are no (%) of patients unless stated otherwise.
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table 5 | Distribution of other non-matching variables at cohort entry date
Pioglitazone cohort (no (%) of patients)
standardised 
difference
exposed to 
pioglitazone 
(n=56 337)
not exposed to 
pioglitazone 
(nearest match 
cohort; n=56 337)
not exposed to 
pioglitazone 
(multiple match 
cohort; n=317 109)
nearest 
match 
cohort
Multiple 
match 
cohort
age at cohort entry date (years)
40-49 6728 (11.94) 5608 (9.95) 27 697 (8.73) 6.37 8.16
50-59 14 881 (26.41) 12 618 (22.40) 66 083 (20.84) 9.36 10.33
60-69 18 366 (32.60) 17 262 (30.64) 94 060 (29.66) 4.22 4.18
≥70 16 362 (29.04) 20 849 (37.01) 129 269 (40.76) 17.00 18.90
Range 40-102 40-106 40.00-107.00 — —
Mean (standard deviation) 63.24 (10.86) 65.38 (11.56) 66.55 (11.71) — —
Median (interquartile range) 63.00 (55.03-71.00) 65.00 (57.00-74.00) 67.00 (58.00-75.00) — —
sex
Male 31 732 (56.33) 30 561 (54.25) 170 181 (53.67) 4.18 3.83
Female 24 605 (43.67) 25 776 (45.75) 146 928 (46.33) 4.18 3.83
no of different diabetes drug classes being used at cohort entry date
1 6905 (12.26) 9961 (17.68) 69 336 (21.87) 15.25 15.99
2 29 216 (51.86) 29 767 (52.84) 176 356 (55.61) 1.96 1.79
3 18 446 (32.74) 15 917 (28.25) 68 964 (21.75) 9.76 10.13
>3 1770 (3.14) 692 (1.23) 2453 (0.77) 13.12 13.41
Diabetes treatment at cohort entry date*
Metformin only 19 622 (34.83) 3496 (6.21) 34 122 (10.76) 75.80 74.90
Sulphonylureas only 7442 (13.21) 2418 (4.29) 18 768 (5.92) 31.96 31.65
Metformin and sulphonylureas 13 659 (24.25) 12 062 (21.41) 82 031 (25.87) 6.76 5.55
Insulin (only or in combination) 2595 (4.61) 20 840 (36.99) 114 382 (36.07) 87.02 86.16
Other drugs (one drug only or combination) 6114 (10.85) 17 521 (31.10) 67 806 (21.38) 51.34 50.40
No treatment 6905 (12.26) 0 0 52.86 52.86
bladder comorbidities at cohort entry date
Urinary incontinence 2960 (5.25) 3455 (6.13) 19 792 (6.24) 3.79 3.35
Urinary tract infection 5336 (9.47) 5774 (10.25) 22 596 (7.13) 2.61 3.12
Pyelonephritis 682 (1.21) 842 (1.49) 5650 (1.78) 2.46 2.66
Urolithiasis 1268 (2.25) 1182 (2.10) 5740 (1.81) 1.05 0.95
Haematuria 1866 (3.31) 1970 (3.50) 8368 (2.64) 1.02 1.40
Urinary retention 556 (0.99) 774 (1.37) 4324 (1.36) 3.58 3.67
Neurogenic bladder 49 (0.09) 66 (0.12) 436 (0.14) 0.95 1.20
Catheterisation 431 (0.77) 602 (1.07) 2955 (0.93) 3.19 3.41
Other comorbidities at cohort entry date
Other urinary tract cancer (excluding bladder cancer) 114 (0.20) 122 (0.22) 869 (0.27) 0.31 0.20
Other cancer (excluding urinary tract cancer) 5663 (10.05) 6538 (11.61) 37 210 (11.73) 5.00 5.97
Chronic obstructive pulmonary disease 5406 (9.60) 6396 (11.35) 33 563 (10.58) 5.74 7.19
use of other drug treatments before cohort entry date
Statins 26 077 (46.29) 24 778 (43.98) 160 948 (50.75) 4.63 4.96
Angiotension receptor blocker 15 795 (28.04) 14 057 (24.95) 81 669 (25.75) 6.99 7.13
Angiotensin converting enzyme inhibitors 31 328 (55.61) 31 746 (56.35) 167 820 (52.92) 1.49 1.89
Benign prostatic hyperplasia 7401 (13.14) 7793 (13.83) 39 108 (12.33) 2.04 2.28
Data are no (%) of patients unless stated otherwise. Treatments initiated at cohort entry date are included. For the pioglitazone exposed group, listed treatments are in addition to pioglitazone.
table 6 | number and crude incidence of bladder cancer cases in pioglitazone cohorts, according to european datasets
Dataset
Cohort
exposed to pioglitazone (n=56 337)
not exposed to pioglitazone 
(nearest matched cohort; n=56 337)
not exposed to pioglitazone 
(multiple matched cohort; n=317 109)
no of 
cases
Crude incidence 
(95% Ci) per 10 000 
person years
no of 
cases
Crude incidence 
(95% Ci) per 10 000 
person years
no of 
cases
Crude incidence 
(95% Ci) per 10 000 
person years
Finland 24 4.42 (2.96 to 6.60) 40 7.51 (5.51 to 10.23) 423 9.34 (8.49 to 10.27)
Sweden 15 20.73 (12.50 to 34.39) 4 5.53 (2.08 to 14.73) 73 10.75 (8.55 to 13.52)
Netherlands GP 10 9.27 (4.99 to 17.24) 10 9.18 (4.94 to 17.06) 61 10.57 (8.23 to 13.59)
Netherlands hospital 27 9.97 (6.84 to 14.53) 21 8.13 (5.30 to 12.47) 161 11.53 (9.88 to 13.46)
UK GP 24 7.61 (5.10 to 11.35) 26 8.89 (6.05 to 13.06) 107 11.32 (9.36 to 13.68)
UK GP-hospital 30 9.33 (6.53 to 13.35) 52 15.99 (12.18 to 20.98) 145 14.73 (12.52 to 17.33)
Pooled dataset 130 7.97 (6.71 to 9.47) 153 9.62 (8.21 to 11.27) 970 10.65 (10.00 to 11.34)
Netherlands hospital,with overlap* 33 10.07 (7.16 to 14.16) 26 8.23 (5.61 to 12.09) 192 11.20 (9.72 to 12.90)
*Patients represented in both Netherlands datasets were removed from the Netherlands hospital dataset.
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(0.44 to 1.66) and 1.12 (0.63 to 2.01) for nearest match 
and multiple match cohorts, respectively; those with a 
 cumulative pioglitazone dose of 40 000 mg had corre‑
sponding hazard ratios of 0.65 (0.33 to 1.26) and 0.81 
(0.44 to 1.47).
Figure 3  presents bladder cancer hazard ratios for 
patients who were ever exposed to pioglitazone for each 
study dataset, plus a meta‑analysis of the summary 
hazard ratios. We saw heterogeneity between popula‑
tions; the hazard ratio for ever exposed groups ranged 
from 0.56 (95% confidence interval 0.31 to 1.00) for the 
Finland dataset to 4.27 (1.26 to 14.46) for the Sweden 
dataset in the nearest matched cohort. However, the 
Sweden dataset was small and only had four bladder 
cancer events in the cohort not exposed to pioglitazone. 
The meta‑analysis, with both fixed and random effect 
models, yielded similar results to the pooled analysis. 
For the multiple matched cohort, the meta‑analysis 
results were also similar (fig 4), but had less heteroge‑
neity between populations, with the hazard ratio in the 
Sweden dataset dropping to 1.52 (0.82 to 2.82).
Data on smoking, body mass index, and HbA1C were 
only available for the Sweden, Netherlands GP, UK GP, 
and UK GP‑hospital datasets. In a pooled analysis of 
the nearest match cohort restricted to these popula‑
tions, the proportion of ever (53%) and never (38%) 
smokers and the mean body mass index (32) did not 
differ between the cohort exposed to pioglitazone and 
Pioglitazone exposure
  Never
  Ever
Duration of pioglitazone exposure
  Never
  <18 months
  18-<48 months
  >48 months
Cumulative pioglitazone dose
  Never
  1-14 000 mg
  14 001-40 000 mg
  >40 000 mg
Reference 
0.99 (0.75 to 1.30)
 
Reference 
1.10 (0.82 to 1.48)
0.78 (0.52 to 1.19)
0.86 (0.44 to 1.66)
 
Reference 
1.05 (0.77 to 1.42)
0.99 (0.66 to 1.46)
0.65 (0.33 to 1.26)
Reference 
0.83 (0.66 to 1.05)
 
Reference 
0.93 (0.71 to 1.22)
0.69 (0.47 to 1.01)
0.76 (0.41 to 1.42)
 
Reference 
0.88 (0.67 to 1.17)
0.86 (0.60 to 1.23)
0.56 (0.30 to 1.06)
0.25 0.5 1.0 1.5 2.0
Exposure Adjusted
Hazard ratio (95% CI)
Hazard ratio (95% CI) Crude
153
130
153
83
35
12
153
79
40
11
No of
events
9.62
7.97
9.62
8.12
7.29
9.37
9.62
7.80
8.72
6.92
Incidence
Crude model
Adjusted model
Fig 1 | adjusted risk estimates for bladder cancer for different pioglitazone exposures using the nearest matched cohort. 
Crude model=pioglitazone exposure variable and a dataset identifier. adjusted model=crude model plus age, sex, 
metformin use, sulphonylurea use, insulin use, use of other diabetes drugs, all exact matching variables, propensity 
scores (divided into five equal groups), and all propensity score variables evaluated at cohort entry date. Ptrend=0.42 and 
0.45 for increasing pioglitazone duration and dose, respectively, using the adjusted model. incidence values measured 
over 10 000 person years
Pioglitazone exposure
  Never
  Ever
Duration of pioglitazone exposure
  Never
  <18 months
  18 to ≤48 months
  >48 months
Cumulative pioglitazone dose
  Never
  1-14 000 mg
  14 001-40 000 mg
  >40 000 mg
Reference 
1.00 (0.83 to 1.21)
 
reference 
1.07 (0.85 to 1.34)
0.85 (0.60 to 1.20)
1.12 (0.63 to 2.01)
 
reference 
1.03 (0.81 to 1.30)
1.02 (0.74 to 1.41)
0.81 (0.44 to 1.47)
Reference 
0.77 (0.65 to 0.92)
 
Reference 
0.81 (0.65 to 1.02)
0.66 (0.47 to 0.92)
0.90 (0.50 to 1.59)
 
Reference 
0.78 (0.62 to 0.98)
0.79 (0.58 to 1.09)
0.64 (0.35 to 1.17)
0.25 0.5 1.0 1.5 2.0
Exposure Adjusted
Hazard ratio (95% CI)
Hazard ratio (95% CI) Crude
970
130
970
83
35
12
970
79
40
11
No of
events
10.65
7.97
10.65
8.12
7.29
9.37
10.65
7.80
8.72
6.92
Incidence
Crude model
Adjusted model
Fig 2 | adjusted risk estimates for bladder cancer for different pioglitazone exposures using the multiple matched cohort. 
Crude model=pioglitazone exposure variable and a dataset identifier. adjusted model=crude model plus age, sex, 
metformin use, sulphonylurea use, insulin use, use of other diabetes drugs, all exact matching variables, propensity 
scores (divided into five equal groups), and all propensity score variables evaluated at cohort entry date. Ptrend=0.85 and 
0.81 for increasing pioglitazone duration and dose, respectively, using the adjusted model. incidence values measured 
over 10 000 person years 
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the cohort not exposed. The proportion of patients with 
HbA1C over 9.0% and the mean HbA1C value were 
lower in the exposed group than the non‑exposed 
group (21.9% v 29.6% and 8.5% v 8.8%, respectively). 
Inclusion of these three covariates into the adjusted 
model reduced the adjusted hazard ratio by 18.7%, 
from 1.02 (95% confidence interval 0.70 to 1.49) to 0.83 
(0.54 to 1.28). Separate introduction of smoking, 
HbA1C, and body mass index into the model reduced 
the adjusted hazard ratio by 10.5%, 11.3%, and 6.3%, 
respectively.
Figure 5 shows stratification of the risk estimates of 
bladder cancer in patients ever exposed to pioglita‑
zone for the nearest match cohort baseline variable. 
We observed a non‑significant sex effect. Female 
patients ever exposed to pioglitazone had a hazard 
ratio of 0.55 (95% confidence interval 0.27 to 1.10), 
whereas male patients had a hazard ratio of 1.11 (0.82 
to 1.50). Effect modification also occurred with respect 
to the source of bladder cancer data. For populations 
where bladder cancer was ascertained from cancer 
registries (Finland, Sweden, UK GP‑hospital datasets), 
the hazard ratio for patients ever exposed to pioglita‑
zone was below unity (0.75 (0.52 to 1.08)). Conversely, 
for populations where cancers were not ascertained 
from cancer registries (Netherlands hospital, Nether‑
lands GP, and UK GP datasets), the hazard ratio was 
above unity (1.51 (0.99 to 2.30)). Other covariates 
showed no effect modification.
Some tumours diagnosed soon after cohort entry 
were possibly pre‑existing and unlikely related to 
 pioglitazone treatment. Exclusion of all bladder cancer 
diagnoses within three months of cohort entry (hazard 
ratio 1.01 (95% confidence interval 0.76 to 1.35)) and 
within 12 months of cohort entry (0.97 (0.69 to 1.35)) had 
little effect.
The study included a mixture of patients with inci‑
dent and prevalent diabetes. Among those with inci‑
dent diabetes (that is, with at least 12 months’ 
membership before first diabetes prescription), the 
adjusted hazard ratio for bladder cancer in patients ever 
exposed to pioglitazone was 0.72 (95% confidence inter‑
val 0.45 to 1.14). However, the corresponding hazard 
ratio for patients with prevalent diabetes (that is, with 
treatment prescriptions for diabetes within 12 months 
of joining database) was 1.24 (0.88 to 1.75).
Our definition of patients ever exposed to pioglita‑
zone was at least one prescription, whereas some 
previous studies used more stringent criteria of at 
least two prescriptions within six months. In a sensi‑
tivity analysis using this more stringent definition, 
the adjusted hazard ratio for patients ever exposed to 
pioglitazone was 0.92 (95% confidence interval 0.66 
to 1.29).
We also did a sensitivity analysis to assess the effect 
of broadening the bladder cancer definition. The 
above results were based on inclusion of malignancy 
neoplasm and carcinoma in situ of the bladder. 
Expansion of the definition to include bladder neo‑
plasms of uncertain and unknown behaviour resulted 
in 17 more events in the group ever exposed to piogli‑
tazone, and 14 more events in the never exposed near‑
est match group. The adjusted hazard ratio was 
similar to the corresponding value using the primary 
definition for bladder cancer. Finally, we assessed 
whether morbidity record source affected the results. 
In a sensitivity analysis limited to datasets with only 
hospital based morbidity data (Finland, Sweden, and 
Netherlands hospital datasets), which typically con‑
tain more severe morbidity than seen in GP records, 
the adjusted hazard ratio was similar to that seen in 
the primary analysis (0.94, 95% confidence interval 
0.69 to 1.28).
discussion
In this study, we found no association between patients 
ever exposed to pioglitazone treatment and risk of blad‑
der cancer. Additionally, no evidence emerged of any 
dose‑response relation with duration or cumulative 
dose of pioglitazone. Examination of pioglitazone 
related risk with the subgroups of selected relevant 
covariates did not identify any subgroups at increased 
risk. Multiple sensitivity analyses also found no associ‑
ation between exposure to pioglitazone and risk of 
bladder cancer.
Finland
Sweden
UK GP
UK GP hospital
Netherlands hospital
Netherlands GP
Meta-analyses (random eect)
Meta-analyses (xed eect)
Pooled data
Q statistic for heterogeneity: 15.34, P=0.009
I2 (total heterogeneity/total variability)
  from random eects model: 68.07%
0.56 (0.31 to 1.00)
4.27 (1.26 to 14.46)
1.04 (0.51 to 2.11)
0.65 (0.35 to 1.21)
1.95 (1.02 to 3.73)
1.23 (0.42 to 3.63)
1.13 (0.65 to 1.95)
1.00 (0.74 to 1.34)
0.99 (0.75 to 1.30)
0.25 1 4 16
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Dataset
Fig 3 | adjusted hazard ratio estimates for bladder cancer in patients ever exposed to 
pioglitazone in the nearest matched cohort 
Finland
Sweden
UK GP
UK GP hospital
Netherlands hospital
Netherlands GP
Meta-analyses (random eect)
Meta-analyses (xed eect)
Pooled data
Q statistic for heterogeneity: 8.26, P=0.142
I2 (total heterogeneity/total variability)
  from random eects model: 40.92%
0.62 (0.40 to 0.95)
1.52 (0.82 to 2.82)
1.21 (0.76 to 1.93)
0.88 (0.57 to 1.38)
1.10 (0.70 to 1.75)
1.28 (0.63 to 2.62)
1.01 (0.77 to 1.32)
0.99 (0.81 to 1.21)
1.00 (0.83 to 1.21)
0.5 10.25 2 4
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Dataset
Fig 4 | adjusted hazard ratio estimates for bladder cancer in patients ever exposed to 
pioglitazone in the multiple matched cohort 
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Comparison with previous studies
Our findings agree with several other large studies with 
multiple years of follow‑up. The KPNC prospective 
cohort study of 193 000 patients with diabetes—one of 
the largest, most informative studies so far—recently 
reported their 10 year follow‑up analysis,10  indicating 
that exposure to pioglitazone was not associated with 
bladder cancer risk. A subgroup analysis limited to 
newly diagnosed diabetes in the KPNC cohort, for 
whom complete diabetic medication data was avail‑
able, similarly found no association with ever exposure 
to pioglitazone and no evidence of a dose‑response 
relation. Two other recent large studies also reported no 
association with pioglitazone exposure. An interna‑
tional study of 1 006 000 patients and mean follow‑up 
of five years reported no excess risk.12  A retrospective 
cohort analysis of 207 000 treated patients with 
 diabetes in the UK with up to 10 years of follow‑up also 
reported no association.11
Conversely, many earlier epidemiological studies 
reported an increased bladder cancer risk in patients 
with diabetes using pioglitazone.6  However, an expert 
working group at the International Agency for Research 
on Cancer, believed that the observed association could 
not consistently rule out confounding, selection bias, 
detection bias, and bias related to indication or severity 
of disease.8  A recent cohort study in the UK reported an 
increased bladder cancer risk in patients treated with 
pioglitazone compared with patients with type 2 diabe‑
tes treated with another diabetes drug.13 But several of 
the early studies had limitations, such as little control 
over treatment allocation bias, or no information on 
known bladder cancer risk factors (such as cigarette 
smoking). Reference group choice might also have 
Age at cohort entry date
  ≥ 70
  60-69
  50-59
  40-49
Congestive heart failure at cohort entry date
  Yes
  No
Diabetic renal complications at cohort entry date
  Never
  Ever
Duration of treated diabetes at cohort entry date
  ≥6
  4-<6
  2-<4
  1-<2
  <1
Sex
  Male
  Female
Other thiazolidinediones before cohort entry date
  Never
  Ever
Propensity score groups at cohort entry date
  5th
  4th
  3rd
  2nd
  1st
Source of bladder cancer data
  Not cancer registry
  Cancer registry
Source of morbidity data
  Only GP
  Including hospital
Year of cohort entry date
  2008-11
  2004-07
  2000-03
1.04 (0.71 to 1.53)
0.99 (0.62 to 1.58)
0.76 (0.32 to 1.80)
NA
0.36 (0.08 to 1.62)
1.04 (0.78 to 1.37)
0.94 (0.69 to 1.28)
1.36 (0.73 to 2.52)
1.22 (0.75 to 1.97)
0.76 (0.36 to 1.60)
0.88 (0.45 to 1.72)
1.69 (0.81 to 3.54)
0.65 (0.33 to 1.26)
1.11 (0.82 to 1.50)
0.55 (0.27 to 1.10)
0.94 (0.70 to 1.27)
1.11 (0.52 to 2.36)
1.59 (0.81 to 3.11)
1.43 (0.72 to 2.85)
0.67 (0.27 to 1.71)
1.23 (0.67 to 2.26)
0.71 (0.43 to 1.17)
1.51 (0.99 to 2.30)
0.75 (0.52 to 1.08)
1.20 (0.68 to 2.13)
0.94 (0.68 to 1.28)
1.07 (0.58 to 1.99)
1.00 (0.70 to 1.45)
0.79 (0.42 to 1.50)
0.5 10.25 2 4
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Fig 5 | adjusted hazard ratios in pioglitazone exposure groups (ever versus never) for stratified analysis of bladder cancer 
incidence, based on pooled dataset for the nearest matched cohort. na=not available 
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introduced bias. Some studies compared patients with 
diabetes using pioglitazone with the general popula‑
tion, whereas other studies compared these patients 
with all other treated patients with diabetes, or patients 
with diabetes on specific drug treatments.
Unlike most previous studies and the recent cohort 
study in the UK,13 we used exact matching as well as 
propensity score matching to minimise treatment allo‑
cation bias. We included duration of treated diabetes, 
type and number of previous treatments, and history of 
diabetic complications as part of the matching algo‑
rithm with the aim of having a reference group that was 
as similar as possible.
We observed that the risk estimate for patients ever 
exposed to pioglitazone was below unity for datasets 
where bladder cancer events were ascertained from can‑
cer registries, but above unity for datasets without can‑
cer registry information, although both results were 
non‑significant. The reason for this difference is unclear, 
but could be related to incomplete recording or misclas‑
sification of bladder cancers in primary care records.
strength and limitations
Strengths of our study included the propensity score 
matched study design, inclusion of data from multiple 
populations rather than one population, the large size 
of the pooled dataset, and several years of follow‑up. 
Our base population of over 1.6 million patients with 
diabetes with up to 10 years of follow‑up makes this one 
of the largest pioglitazone studies so far. One protocol 
covering six different European populations and single 
data analysis plans used across them ensured that the 
same approach was used by all investigators in match‑
ing selection and creation of analytical variables. We 
included variables fixed at baseline and time depen‑
dent variables, in addition to many stratified analyses 
to identify potential effect modification and various 
sensitivity analyses to assess robustness. 
Our study had several limitations, including our pri‑
mary analysis not being adjusted for smoking, body 
mass index, or HbA1C because not all datasets con‑
tained the necessary information. However, we per‑
formed analyses restricted to populations with this 
information. 
Another limitation was left truncation of prescribing 
information in the Sweden dataset. Pioglitazone has 
been available since 2001, but the Swedish medication 
database did not start until July 2005 and contained no 
prior prescription information. Information on pioglita‑
zone use before July 2005 was therefore missing, result‑
ing in misclassification of exposure to the drug. 
Moreover, left truncation of medication information 
could also have caused misclassification of the match‑
ing variables, resulting in residual treatment allocation 
bias in the Sweden dataset. Left truncation of prescrip‑
tion information is an inherent limitation of database 
studies that include prevalent diabetics. This effect was 
not present in our subgroup analysis of patients with 
incident diabetes, for whom full prescribing informa‑
tion was available. 
A further potential limitation of this study (and other 
published studies) was the unavailability of data on the 
incidence of bladder cancer among pioglitazone users 
beyond 10 years after initiation of treatment. Finally, we 
planned to examine cancer tumour stage and grade, 
but the information was not available for most of the 
tumours. 
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